Getting persuasive about the non-invasive:assessing liver fibrosis in practice-without a biopsy  

作　　者：Nida Ansari Patrick Twohig 

机构地区：[1]Department of Internal Medicine,St.Joseph’s University Medical Center,Paterson,NJ,USA [2]Division of Gastroenterology and Hepatology,University of Rochester Medical Center,Rochester,NY,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第5期879-881,共3页肝胆外科与营养（英文）

摘　　要：Chronic liver disease(CLD)is the 10th leading cause of death in the United States(1,2).The early detection of liver fibrosis is crucial in minimizing disease progression and risk of death(2).While the gold standard for diagnosis is liver biopsy,it is invasive,costly,and less accessible than non-invasive fibrosis assessment tools which utilize blood work and/or imaging(2,3).The growing prevalence of CLD emphasizes the importance of noninvasive liver disease assessments(NILDA),with the availability of blood base and imaging assessments(3).

关 键 词：Hepatic fibrosis liver biopsy CIRRHOSIS BIOMARKER 

分 类 号：R575.2[医药卫生—消化系统]